Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News
Wie SuperBuzz am Freitag parabolisch durchstartete - und warum das erst der Anfang sein könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWF0 | ISIN: US87990A1060 | Ticker-Symbol:
NASDAQ
29.08.25 | 21:56
1,130 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TENAYA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TENAYA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TENAYA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16:18Tenaya Therapeutics, Inc.: Tenaya Therapeutics Presents Interim Data from MyClimb Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 20253
07.08.Tenaya Therapeutics GAAP EPS of -$0.14 beats by $0.0618
06.08.Tenaya Therapeutics, Inc. - 10-Q, Quarterly Report3
06.08.Tenaya Therapeutics, Inc. - 8-K, Current Report2
06.08.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update139Enrollment Complete in Cohorts 1 and 2 of MyPEAK-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE-1 Phase...
► Artikel lesen
30.07.Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies18
TENAYA THERAPEUTICS Aktie jetzt für 0€ handeln
30.07.Tenaya completes enrollment in both dose cohorts for HCM gene therapy14
30.07.Tenaya Therapeutics, Inc.: Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed153Enrollment in Both Dose Cohorts of the MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected...
► Artikel lesen
30.05.Tenaya Therapeutics, Inc. - 8-K, Current Report20
16.05.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)311SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...
► Artikel lesen
13.05.Tenaya Therapeutics, Inc.: Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting6
07.05.Tenaya Therapeutics GAAP EPS of -$0.246
07.05.Tenaya Therapeutics, Inc. - 10-Q, Quarterly Report4
07.05.Tenaya Therapeutics, Inc. - 8-K, Current Report5
25.04.H.C. Wainwright maintains Buy on Tenaya Therapeutics stock15
24.04.Tenaya reports progress in ARVC gene therapy study6
24.04.Tenaya berichtet über Fortschritte in der Gentherapie-Studie für ARVC20
24.04.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Presents Interim Data from RIDGE Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 20254
18.04.Tenaya Therapeutics, Inc. - 8-K, Current Report6
31.03.Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting232TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with...
► Artikel lesen
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2